Table: Aska Pharmaceutical Holdings -2024/25 group results

ASKA Pharmaceutical Holdings

12/05/2025 07:35

May 12 (Reuters)- 
          Aska Pharmaceutical Holdings Co., Ltd. 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2025    Mar 31, 2024   Mar 31, 2026     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           64.14           62.84          75.00                 
               (+2.1 pct)      (+3.9 pct)     (+16.9 pct)              
  Operating        5.33            6.50           6.80                 
               (-18.0 pct)     (+27.3 pct)    (+27.5 pct)              
  Recurring        5.11            6.52           6.80                 
               (-21.7 pct)     (+24.6 pct)    (+33.1 pct)              
  Net
  Net              5.10            7.55           5.20                 
               (-32.4 pct)     (+78.0 pct)    (+1.9 pct)               
  EPS          179.95 yen      266.51 yen     183.44 yen               
  Ann Div       55.00 yen       40.00 yen      55.00 yen               
  -Q2 Div       25.00 yen       20.00 yen      27.00 yen               
  -Q4 Div       30.00 yen       20.00 yen      28.00 yen               
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd..
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T